Translational Psychiatry
September 28, 2022
Li Ma, Long Wang, Lijia Chang et al.
( R,S )-ketamine is known to elicit persistent prophylactic effects in rodent models of depression. However, the precise molecular mechanisms underlying its action remain elusive. Using RNA-sequencing analysis, we searched for novel molecular target(s) that contribute to the prophylactic effects of ( R )-ketamine, a more potent enantiomer of ( R,S )-ketamine in chronic restraint stress (CRS)...
Frontiers in Psychiatry
September 28, 2022
K. Hassan, W. Struthers, Aditya Sankarabhotla et al.
25 citations
Intravenous and intranasal ketamine have been shown to be effective therapeutic options in patients suffering from treatment-resistant depression (TRD). The use of sublingual (SL), rapid dissolve ketamine tablets (RDT) offers a novel approach for delivery for mental health indications. This study assessed the effectiveness and safety of self-administration of off-label, SL, rapid dissolve...
JAMA Psychiatry
September 28, 2022
Hugo Bottemanne, Orphée Morlaàs, Anne Claret et al.
59 citations
Key Points Question What are the effects of ketamine on belief updating in patients with treatment-resistant depression (TRD)? Findings This case-control study in patients with TRD showed that belief updating became more optimistically biased as soon as 4 hours after a first ketamine infusion. This early cognitive effect of ketamine was formalized by stronger asymmetrical reinforcement learning...
International Journal of Molecular Sciences
September 28, 2022
Dominika Psiuk, Emilia Magdalena Nowak, Natalia Dycha et al.
36 citations
This publication discusses two compounds belonging to the psychoactive substances group which are studied in the context of depression treatment—psilocybin and esketamine. The former is a naturally occurring psychedelic. The latter was invented in the laboratory exactly 60 years ago. Although the substances were controversial in the past, recent studies indicate the potential of those...
Science Signaling
September 27, 2022
Leslie K. Ferrarelli
A stress hormone enables the antidepressant action of ketamine.
Indian Journal of Behavioural Sciences
September 26, 2022
Akanksha Varshney, Shravan Kumar, Ved Prakash Gupta et al.
1 citation
In treatment-resistant unipolar and bipolar depression, there is increasing evidence to support the fast, although the short-lived antidepressant effect of ketamine, a non-competitive glutamate N-methyl-D-aspartate receptor antagonist. Ketamine has been shown to cause transient mood elevation or euphoria, dissociative symptoms and psychotomimetic effects when administered in unipolar or bipolar...
Translational Neuroscience
September 21, 2022
Yiwei Shen, Feng Lv, Su Min et al.
Abstract: Background: A growing number of studies have demonstrated that ketamine induces rapid and sustained antidepressant action. Neuronal nitric oxide synthase (nNOS) signaling has been explored for the treatment of neuropsychiatric disorders for decades. But the effect of ketamine on nNOS signaling is poorly understood. The aim of the present study was to investigate the effect of ketamine...
American Journal of Psychiatry
September 21, 2022
Rebecca B Price, Crystal Spotts, Benjamin Panny et al.
Background: Intravenous ketamine, which displays rapid antidepressant properties, is posited to reverse depression by rapidly enhancing neuroplasticity. We tested whether an automated, computer-based approach could efficiently leverage enhanced neuroplasticity to extend the durability of rapid clinical response. Methods: 154 adults (age 18–60) with unipolar, treatment-resistant depression were...
Frontiers in Psychiatry
September 21, 2022
Laurent Elkrief, Olivier Payette, Jean-Nicolas Foucault et al.
15 citations
About a third of patients suffering from major depression develop treatment-resistant depression (TRD). Although repetitive transcranial magnetic stimulation (rTMS) and intravenous ketamine have proven effective for the management of TRD, many patients remain refractory to treatment. We present the case of a patient suffering from bipolar TRD. The patient was referred to us after failure to...
Synapse
September 19, 2022
Rose Temizer, Yi‐Wen Chen, Chiye Aoki
Anorexia nervosa (AN) is a mental illness with the highest rates of mortality and relapse, and no approved pharmacological treatment. Using an animal model of AN, called activity‐based anorexia (ABA), we showed earlier that a single intraperitoneal injection of ketamine at a dose of 30 mg/kg (30mgKET), but not 3 mg/kg (3mgKET), has a long‐lasting effect upon adolescent females of ameliorating...
bioRxiv Preprint Server
September 19, 2022
Stanislav Rozov, Roosa Saarreharju, Stanislav Khirug et al.
preprint
Nitrous oxide (N2O; laughing gas) has recently been reported as a putative rapid-acting antidepressant, but little is known about the underlying mechanisms. We performed transcriptomics, in situ hybridization, and electrophysiological studies to examine the potential shared signatures induced by 1 h inhalation of 50% N2O and a single subanesthetic dose of ketamine in the medial prefrontal...
Health Psychology Research
September 15, 2022
Danyon J Anderson, Jessica Zhou, David Cao et al.
Ketamine is a common medical anesthetic and analgesic but is becoming more widely used as a recreational drug. Significant side effects on the urinary tract are associated with frequent recreational ketamine use most notably ketamine-induced cystitis (KIC). Regular ketamine consumption has been shown to increase the risk of cystitis symptoms by 3- to 4-fold, and cessation of ketamine use is...
Ketamine Revisited - New Insights into NMDA Inhibitors
September 14, 2022
Maiko Satomoto
Electroconvulsive therapy (ECT) is highly effective both Major Depressive Disorder (MDD) and Bipolar Disorder (BD). Ketamine, an antagonist of the N-Methyl-D-aspartate receptor, has been described to have antidepressant properties. There is a hypothesis that ECT performed with anesthesia using ketamine is more effective than conventional ECT. Also, although ECT is the gold standard for BD and...
Ketamine Revisited - New Insights into NMDA Inhibitors
September 14, 2022
Atamjit Singh, Preet Mohinder Singh Bedi
Ketamine is a phencyclidine derivative and N-methyl-D-aspartate receptor antagonist, widely popular as a dissociative anesthetic. Its use as an anesthetic in humans was progressively fallen out due to its associated adverse effects and the emergence of newer and safer anesthetics. In recent few decades, various reports related to its efficacy in the treatment of resistant depression with...
Ketamine Revisited - New Insights into NMDA Inhibitors
September 14, 2022
Ouelhazi Afef, Rudy Lussiez, Molotchnikoff Stephane
1 citation
Sensory systems need to process signals in a highly dynamic way to efficiently respond to variations in the animal’s environment. For instance, several studies showed that the visual system is subject to neuroplasticity since the neurons’ firing changes according to stimulus properties. This dynamic information processing might be supported by a network reorganization. Since antidepressants...
Ketamine Revisited - New Insights into NMDA Inhibitors
September 14, 2022
Tahani K. Alshammari, Sarah Alseraye, Nouf M. Alrasheed et al.
Our knowledge regarding pathological and treatment resistance mechanisms involved in depression is far from understood. Sexual dimorphism in this topic is well acknowledged. However, the need to highlight sex-based discrepancies is unmet. Ketamine, the dissociative anesthetic, has emerged as a rapid antidepressant. This chapter reviewed sexual dimorphism in pharmacological and genetic models of...
Ketamine Revisited - New Insights into NMDA Inhibitors
September 14, 2022
Bhargab Deka, Biswajit Dash, Alakesh Bharali et al.
1 citation
Ketamine has been extensively used in the medical field for more than 50 years, but its exact mechanism of action remains unknown. It’s used to induce dissociative anesthesia (a state of profound analgesia, amnesia with light sleep, immobility, and a sense of disassociation from one’s own body and surroundings). Clinical studies on ketamine as a dissociative anesthetic, a model for psychosis,...
Ketamine Revisited - New Insights into NMDA Inhibitors
September 14, 2022
Patrycja Kleczkowska, Malgorzata Zaremba
5 citations
Ketamine is a derivative of phencyclidine with unique anesthetic, analgesic, as well as antidepressant pharmacological properties. Despite its clinical use, ketamine is classified on the list with new psychoactive substances having psychedelic properties. The abuse trend of ketamine increasing globally, and it became a common club drug over the past few decades. Of note, recreational use of...
The Journal of Clinical Psychiatry
September 12, 2022
P. Oliver, A. Snyder, R. Feinn et al.
Introduction: Few studies have been published to date exploring the effectiveness of ketamine for treatment-resistant depression (TRD) in large clinical samples. We report on the clinical outcomes of a large cohort treated with ketamine as part of clinical practice. Methods: Deidentified electronic chart data were obtained from a multisite private ketamine infusion clinic for 424 patients with...
Anesthesiology
September 12, 2022
Albert Dahan, Erik Olofsen, Thomas K. Henthorn et al.
3 citations
We thank Bowdle et al.1 for their interest in our article,2 and for the important issue they raise, paraphrased as follows: what is the best anthropocentric description of the "mind-altering" effects of a heterogeneous group of compounds and drugs that act at the brain and cause significant changes in mental state. The group of drugs that we are referring to includes N-methyl-d-aspartate (NMDA)...